At the World AMR Congress, Recce Pharmaceuticals contributes by making strides with a synthetic compound designed to target bacterial mutations, underscoring the need for innovation in addressing antimicrobial resistance (AMR). “Our compound is entirely synthetic,” Graham said. “We started with first principles, designing a compound that remains effective with repeated use.”